Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amplifon SpAAMFPF 79 Days Sales Outstanding is 34.74 as of Jun. 2026, which is 4% below its 10-year median of 36.09. GuruFocus rates AMFPF with a GF Score™ of 79/100 and a GF Value™ of $27.48 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 118 Medical Distribution companies, Amplifon SpA ranks better than 90.68% on this metric.
Amplifon SpA's average Accounts Receivable for the
three
months ended in Jun. 2026 was $266 Mil. Amplifon SpA's Revenue for the
three
months ended in Jun. 2026 was $698 Mil.
Hence, Amplifon SpA's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 34.74.
The historical rank and industry rank for Amplifon SpA's Days Sales Outstanding or its related term are showing as below:
AMFPF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 31.07 Med: 36.09 Max: 45.44
Current: 34.31
During the past 13 years, Amplifon SpA's highest Days Sales Outstanding was 45.44. The lowest was 31.07. And the median was 36.09.
AMFPF's Days Sales Outstanding is ranked better than 90.68% of 118
companies
in the Medical Distribution industry
Industry Median: 78.51
vs AMFPF: 34.31
Amplifon SpA's Days Sales Outstanding
increased
from Jun. 2025 (33.43) to Jun. 2026 (34.74).
Amplifon SpA (OTCPK:AMFPF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Amplifon SpA Days Sales Outstanding Related Terms
Amplifon SpA Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Amplifon SpA's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMFPF vs MCK, COR, CAH: Days Sales Outstanding Comparison
For the Medical Distribution subindustry, Amplifon SpA's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amplifon SpA Days Sales Outstanding vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Amplifon SpA's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Amplifon SpA's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amplifon SpA (AMFPF) has a Days Sales Outstanding of 34.74 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Amplifon SpA and its competitors. This is near median its historical median of 36.09. Over the past decade, Amplifon SpA's Days Sales Outstanding has ranged from 31.07 to 45.44. According to the industry distribution chart, Amplifon SpA ranks #11 out of 118 companies in the Medical Distribution industry, placing it in the top 9.3%.
Is Amplifon SpA's Days Sales Outstanding too high?
Amplifon SpA's current Days Sales Outstanding of 34.74 is near median its 10-year median of 36.09. Over the past 10 years, this metric has ranged from a low of 31.07 to a high of 45.44. The Medical Distribution industry median Days Sales Outstanding is 78.51. Amplifon SpA's value of 34.74 is 55.8% below this industry median. Based on the distribution chart, Amplifon SpA ranks #11 out of 118 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Amplifon SpA has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Amplifon SpA's Days Sales Outstanding compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Amplifon SpA ranks #11 out of 118 companies for Days Sales Outstanding. This places Amplifon SpA in the top 9% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 78.51. Amplifon SpA's value of 34.74 is 55.8% below this benchmark. Historically, Amplifon SpA's own Days Sales Outstanding has ranged from 31.07 to 45.44 over the past decade. While the company's 10-year median is 36.09 vs. the industry median of 78.51, Amplifon SpA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Distribution company?
The median Days Sales Outstanding among Medical Distribution companies is 78.51, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amplifon SpA's current Days Sales Outstanding of 34.74 is 55.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Amplifon SpA and its competitors. For the Medical Distribution industry, the median Days Sales Outstanding is 78.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amplifon SpA's current Days Sales Outstanding is 34.74, which is near median its own 10-year median of 36.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplifon SpA stock overvalued right now?
Based on GuruFocus' analysis, Amplifon SpA (AMFPF) is currently considered Possible Value Trap. The stock's GF Value™ is $27.48, compared to a current price of $11.21 — trading 59.2% below its estimated fair value. The current Days Sales Outstanding is 34.74, which is near median its 10-year median of 36.09 and 55.8% below the Medical Distribution industry median of 78.51. Amplifon SpA's overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Amplifon SpA (AMFPF), the current Days Sales Outstanding is 34.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amplifon SpA (AMFPF) Overvalued in 2026?
Based on GuruFocus' analysis, Amplifon SpA stock appears to be undervalued.
The current stock price of $11.21 is trading 59.2% below its estimated GF Value™ of $27.48.
GuruFocus considers Amplifon SpA to be Possible Value Trap.
Key valuation signals for AMFPF:
Days Sales Outstanding: 34.74 (near median its 10-year median of 36.09)
GF Value™: $27.48 vs. price of $11.21 (59.2% below fair value)
Industry Position: 55.8% below the Medical Distribution median (#11 of 118)
No single metric tells the full story. See the AMFPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amplifon SpA provides customizable hearing solutions and services through a distribution network of network affiliates, corporate shops, franchises, and shop-in-shops. The company operates in three segments based on geography: the Americas; Europe, the Middle East, and Africa; and Asia-Pacific. It generates the majority of its revenue in the EMEA region. It operates under a variety of brands in these regions, including Amplifon, Beter Horen, Maxtone, and Miracle-Ear.
79GF Score
Get the complete analysis for AMFPF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMFPF has been successfully added to your 
